Addition of artesunate to standard antimalarial drugs reduces treatment failure - 24/08/11
Abstract |
Question |
What is the effect of adding artesunate to existing drug regimens for people with acute uncomplicated Plasmodium falciparum malaria?
Study design |
Systematic review with meta-analysis.
Main results |
16 trials met inclusion criteria. Standard antimalarial drugs in the trials varied (sulfadoxine–pyrimethamine: 7 RCTs; amodiaquine: 3 RCTs; chloroquine: 3 RCTs; mefloquine: 3 RCTs). Adding artesunate for 3 days to standard antimalarial drugs significantly reduced 14 and 28 day's failure rates compared with standard drugs alone (15 RCTs; OR for failure by 14 day 0.20, 95% CI 0.17 to 0.25; OR for failure by 28 days 0.23, 95% CI 0.19 to 0.28). Addition of artesunate for 1 day was not as effective as 3 days, but still significantly reduced failure rates compared with standard drugs alone (6 RCTs; OR for failure by 14 days 0.61, 95% CI 0.48 to 0.77; OR for failure by 28 days 0.68, 95% CI 0.53 to 0.89). The incidence of side effects was similar in both groups.
Authors’ conclusions |
Adding artesunate to a standard antimalarial drug regimen for 3 days leads to a consistent decrease in treatment failure at 14 days, irrespective of the standard antimalarial drug used.
Le texte complet de cet article est disponible en PDF.Keywords : Uncomplicated malaria, Artesunate, Treatment failure, Systematic review
Plan
Abstracted from: Adjuik M, Agnamey P, Babiker A et al. International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363: 9–17. |
Vol 8 - N° 3
P. 156-158 - juin 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?